Transcatheter Tricuspid Valve Replacement for Torrential Tricuspid Regurgitation in Complex Adult Congenital Heart Disease Authors: Emily Morris, Ali Roomi, Massimiliano Costello, Russell Franks, Joanna Lim, Saul Myerson, James D. Newton, Elizabeth Orchard, Sam Dawkins, Thomas J. Cahill Published: 2026 ABSTRACT BackgroundSevere tricuspid regurgitation (TR) carries high morbidity and is often undertreated in patients with complex congenital heart disease and prohibitive surgical risk.Case SummaryA 33-year-old woman with complex congenital heart disease and multiple prior surgeries presented with progressive right-sided heart failure and torrential TR. Imaging demonstrated septal leaflet splinting by a transvenous pacing lead. She was unsuitable for surgery or transcatheter edge-to-edge repair. Following Heart Team assessment, transcatheter tricuspid valve replacement with a 48 mm EVOQUE valve (Edwards Lifesciences) was performed. Despite procedural challenges including delivery system septal bias, implantation was successful with mild residual TR and early symptomatic improvement.DiscussionTranscatheter tricuspid valve replacement is an emerging option for high-risk patients. This case demonstrates feasibility in complex congenital anatomy with pacing leads, a group under-represented in current evidence.Take-Home MessagesTranscatheter tricuspid valve replacement expands treatment options in high-risk congenital tricuspid regurgitation. Careful imaging and Heart Team planning are essential for success. History of Presentation A 33-year-old woman with complex congenital heart disease presented with progressive right-sided heart failure, including worsening exertional breathlessness, peripheral edema, and recurrent fluid overload requiring intravenous diuresis. Past Medical History Her underlying diagnosis was pulmonary atresia with ventricular septal defect (tetralogy of Fallot variant) with a small left pulmonary artery. She underwent staged childhood palliation with a left modified Blalock-Taussig shunt (1992) and a right internal mammary artery–to–right pulmonary artery shunt (1993), followed by complete repair of pulmonary atresia in 1996 with a bifurcated pulmonary homograft and pericardial enlargement of the right ventricle (RV) outflow tract, with an epicardial pacing system. Subsequent interventions included bilateral pulmonary artery stenting (2003), and her pacing system was upgraded to a transvenous abdominal system. In 2016, she required reconstruction of the left and right pulmonary arteries with Dacron graft; replacement of the pulmonary homograft with a custom-made right ventricle–to–pulmonary artery (RV–PA) conduit; and pacemaker revision (left axillary endocardial VVI system). Her course was complicated by recurrent atrial arrhythmias and subsequent left pulmonary vein stenosis with successful stenting. In 2025, the patient was admitted with severe volume overload and acute kidney injury in the context of an intermittent junctional rhythm. Clinical improvement was achieved with aggressive intravenous diuresis; however, persistent severe tricuspid regurgitation (TR) prompted evaluation for transcatheter intervention. Investigations A 6-minute walk test performed on 2 L oxygen demonstrated impaired functional capacity, with resting oxygen saturations of 88% falling to 74% at peak exercise. The Borg rating of perceived exertion was 7/10 with a total walking distance of 340 m. Transthoracic and transesophageal echocardiography demonstrated a trileaflet tricuspid valve with torrential TR. There was a triangular Doppler profile suggesting equalization of right atrial and ventricular pressures and hepatic vein systolic flow reversal. There was severe right heart remodeling with a markedly dilated right atrium and ventricle. The RV showed combined pressure and volume overload with impaired longitudinal function. Left ventricle size and systolic function were preserved. The RV–PA conduit was visualized without obstruction. Cardiac magnetic resonance imaging confirmed torrential TR (regurgitant fraction 66%), due to annular dilation and septal leaflet splinting by a transvenous pacemaker lead (Figure 1). The tricuspid valve coaptation gap diameter was 1.6 cm. There was severe RV dilation with moderately reduced systolic function.Figure 1Preprocedural Cardiac Magnetic Resonance ImagingPreprocedural cardiac magnetic resonance imaging 4-chamber (horizontal long axis) view demonstrating pacing lead in the right atrium passing through the tricuspid valve (left image, long arrow); the tricuspid valve (short arrow); and the broad jet of tricuspid regurgitation on flow imaging (right image, dashed arrow).RV = right ventricle. Preprocedural Cardiac Magnetic Resonance Imaging Preprocedural cardiac magnetic resonance imaging 4-chamber (horizontal long axis) view demonstrating pacing lead in the right atrium passing through the tricuspid valve (left image, long arrow); the tricuspid valve (short arrow); and the broad jet of tricuspid regurgitation on flow imaging (right image, dashed arrow). RV = right ventricle. Right heart catheterization demonstrated a mean right atrial pressure of 31 mm Hg, a RV pressure of 46/10 mm Hg, and a pulmonary artery pressure of 50/18 mm Hg (mean 28 mm Hg). Cardiac output was 2.97 L/min with a cardiac index of 1.75 L/min/m2. Cardiac computed tomography further evaluated the tricuspid anatomy (Figure 2). This confirmed a trileaflet tricuspid valve with a RV pacing lead inserted into the basal septum immediately below the tricuspid annulus. The perimeter of the tricuspid annulus was 139.8 mm (perimeter-derived diameter of 44.5 mm).Figure 2Preprocedural Cardiac Computed Tomography With Multiplanar Reconstruction, Acquired as a Rotational “Spin” About the Tricuspid Valve to Define the Relationship of the Pacemaker Lead to the Valve(Left) Long-axis reconstruction through the right atrium and right ventricle. (Right) Orthogonal short-axis reconstruction through the right and left ventricles, demonstrating the pacing lead crossing the posteroseptal commissure of the tricuspid valve and embedding in the right ventricular septum. LAO = left anterior oblique; MPR = multiplanar reconstruction; RAO = right anterior oblique. Preprocedural Cardiac Computed Tomography With Multiplanar Reconstruction, Acquired as a Rotational “Spin” About the Tricuspid Valve to Define the Relationship of the Pacemaker Lead to the Valve (Left) Long-axis reconstruction through the right atrium and right ventricle. (Right) Orthogonal short-axis reconstruction through the right and left ventricles, demonstrating the pacing lead crossing the posteroseptal commissure of the tricuspid valve and embedding in the right ventricular septum. LAO = left anterior oblique; MPR = multiplanar reconstruction; RAO = right anterior oblique. Management The case was discussed in a multidisciplinary congenital and structural Heart Team meeting. The patient had symptomatic, torrential, mixed-etiology TR due to annular dilatation and pacemaker lead splinting of the septal leaflet. RV function was impaired. She had previously been declined for heart–lung transplantation and was prohibitively high risk for surgical tricuspid valve replacement. Because of lead splinting, her anatomy was unfavorable for transcatheter edge-to-edge repair. Following extensive Heart Team consideration and patient discussion, we elected to perform transcatheter tricuspid valve replacement (TTVR) using a 48 mm EVOQUE valve system. The Heart Team discussion highlighted key procedural risks, particularly device anchoring challenges due to the pacing lead, risk of acute RV failure, and uncertainty about long-term valve function. The procedure was performed under general anesthesia with transesophageal echocardiographic guidance. Baseline imaging demonstrated dilated right heart chambers with moderate RV systolic dysfunction and torrential TR (Video 1). Right femoral venous access was obtained using ultrasound and micropuncture technique. An Agilis catheter was used to advance a Safari wire into the RV and the EVOQUE delivery system was positioned across the tricuspid valve. There was marked septal bias of the delivery system despite all steering maneuvers, likely due to abnormal rotation of the heart following prior cardiac surgery (Figure 3). Anchor engagement was confirmed for all leaflets. Due to persistent septal bias, the valve was deployed under pacing at 120 beats/min for stability.Figure 3Intraprocedural Fluoroscopy in the Right Anterior Oblique Projection (RAO 30°) During Transcatheter Tricuspid Valve Replacement With the EVOQUE System, Captured at the Anchor-Exposure StepThe EVOQUE delivery system, advanced over a Safari wire, lies across the tricuspid valve between the right atrium (RA) and right ventricle (RV), with the device anchors exposed before leaflet capture and valve release. The pre-existing permanent pacemaker (PPM) lead is seen traversing the right heart. Intraprocedural Fluoroscopy in the Right Anterior Oblique Projection (RAO 30°) During Transcatheter Tricuspid Valve Replacement With the EVOQUE System, Captured at the Anchor-Exposure Step The EVOQUE delivery system, advanced over a Safari wire, lies across the tricuspid valve between the right atrium (RA) and right ventricle (RV), with the device anchors exposed before leaflet capture and valve release. The pre-existing permanent pacemaker (PPM) lead is seen traversing the right heart. Postimplant imaging demonstrated a well-seated prosthesis with mild residual TR and a mean gradient of 2 mm Hg (Figure 4, Video 2). Hemostasis was achieved using preplaced ProStyle suture closure devices. The patient’s hemodynamics were stable after the postprocedure with no evidence of RV failure. She was extubated immediately afterward and returned to the ward. Oral anticoagulation was restarted the same day, and she remained in hospital for postprocedural observation and optimization of volume status. A pacemaker check confirmed a normally functioning device with no effect from jailing the lead behind the EVOQUE frame. RV sensing, capture threshold, and lead impedance were stable compared with preprocedure values.Figure 4Final Fluoroscopic Acquisition in the Right Anterior Oblique Projection (RAO 30°) Following Deployment of a 48 mm EVOQUE Valve, Which is Well-Seated Within the Tricuspid Annulus Between the RA and RVThe pre-existing permanent pacemaker (PPM) lead is jailed against the annulus by the device frame. Abbreviations as in Figure 3.Visual SummaryTranscatheter Tricuspid Valve Replacement in Complex Adult Congenital Heart Disease (ACHD)The visual summary illustrates the clinical presentation, Heart Team decision-making, procedural challenges, and early outcomes following transcatheter tricuspid valve replacement with a 48-mm EVOQUE valve in a patient with complex ACHD and torrential tricuspid regurgitation. Despite distorted right heart anatomy and a transvalvular pacing lead, successful valve implantation was achieved with mild residual tricuspid regurgitation, preserved pacing system function, and early symptomatic and functional improvement. PA = pulmonary artery; RA = right atrium; RV = right ventricle; TEE = transesophageal echocardiography; TEER = transcatheter edge-to-edge repair; TOF = tetralogy of Fallot; TR = tricuspid regurgitation; TTVR = transcatheter tricuspid valve replacement; VSD = ventricular septal defect. Final Fluoroscopic Acquisition in the Right Anterior Oblique Projection (RAO 30°) Following Deployment of a 48 mm EVOQUE Valve, Which is Well-Seated Within the Tricuspid Annulus Between the RA and RV The pre-existing permanent pacemaker (PPM) lead is jailed against the annulus by the device frame. Abbreviations as in Figure 3. Transcatheter Tricuspid Valve Replacement in Complex Adult Congenital Heart Disease (ACHD) The visual summary illustrates the clinical presentation, Heart Team decision-making, procedural challenges, and early outcomes following transcatheter tricuspid valve replacement with a 48-mm EVOQUE valve in a patient with complex ACHD and torrential tricuspid regurgitation. Despite distorted right heart anatomy and a transvalvular pacing lead, successful valve implantation was achieved with mild residual tricuspid regurgitation, preserved pacing system function, and early symptomatic and functional improvement. PA = pulmonary artery; RA = right atrium; RV = right ventricle; TEE = transesophageal echocardiography; TEER = transcatheter edge-to-edge repair; TOF = tetralogy of Fallot; TR = tricuspid regurgitation; TTVR = transcatheter tricuspid valve replacement; VSD = ventricular septal defect. Outcome and Follow-Up Early postprocedural transthoracic echocardiography demonstrated a well-seated EVOQUE valve with a mean pressure gradient of 4 mm Hg and mild residual TR, comprising a small transvalvular jet and a lateral paravalvular component. The RV remained dilated but appeared smaller compared with baseline, with improved systolic function. In the immediate postprocedural period, the patient developed thrombocytopenia, with her platelet count falling from 159 × 109/L preprocedure to a nadir of 91 × 109/L. There was no clinical evidence of bleeding or hemolysis. The case was reviewed at the Adult Congenital Heart Disease (ACHD) multidisciplinary team meeting, where transient platelet reduction following transcatheter valve implantation was considered the most likely mechanism. Conservative management was adopted with interval monitoring. Platelet count subsequently improved to 147 × 109/L at 4-week review. At outpatient follow-up, the patient reported initial symptomatic improvement, without palpitations or fluid retention. Weight remained stable and the jugular venous pressure was lower than preprocedure. Her bumetanide was reduced by 2 mg. On repeat 6-minute walk test, the patient walked for 380 m, with a lower level of subjective exertion (4/10) and improved exercise tolerance compared with baseline. The patient continues under specialist ACHD follow-up with planned interval imaging and device follow-up every 6 months. Discussion Severe TR is associated with substantial morbidity and mortality.1,2 Although contemporary European guidelines recommend surgery as the gold standard for severe primary or secondary TR, this is often not feasible in high-risk patients with significant perioperative mortality. In such cases, transcatheter tricuspid valve interventions are increasingly adopted as a Class IIa option following Heart Team assessment.2 This case illustrates guideline-directed management in a complex patient with torrential TR, advanced right heart remodeling, multiple congenital surgeries, and transvenous pacing leads, rendering both surgery and transcatheter edge-to-edge repair unsuitable. In line with European Society of Cardiology recommendations, careful evaluation of TR mechanism, RV function, and procedural feasibility was undertaken within a dedicated congenital and structural Heart Team before TTVR.2 Emerging evidence supports the use of TTVR in such high-risk cohorts. The TRISCEND II trial demonstrated that TTVR using the EVOQUE system, in addition to optimal medical therapy, results in significant improvements in symptoms, functional capacity, and quality of life compared with medical therapy alone, with benefits evident from 30 days to 1 year.3 Meta-analytic data similarly demonstrate high procedural success, low early mortality, and meaningful functional improvement after TTVR.4 Transvenous pacing leads introduce additional complexity during TTVR. Approximately one-third of patients undergoing TTVR have cardiac implantable electronic devices, and lead–valve interactions may affect device positioning and imaging.5 However, registry data suggest that lead entrapment is generally safe, with low rates of lead dysfunction or adverse clinical outcomes, supporting a strategy of proceeding without routine lead extraction in selected patients. However, risks remain, including lead malfunction, imaging challenges, and limitations in future lead management.5 Transient thrombocytopenia was observed following TTVR in our patient. This is increasingly recognized after transcatheter tricuspid interventions, particularly TTVR, with recent data demonstrating a mean platelet count reduction of approximately 40% following EVOQUE implantation and spontaneous recovery by discharge.6 Proposed mechanisms include interactions between circulating blood elements and prosthetic valve material, although the precise pathophysiology remains incompletely understood. Importantly, thrombocytopenia has not been associated with increased mortality or bleeding complications, and conservative management is generally appropriate.6,7 Previous reports have demonstrated the feasibility of EVOQUE TTVR in patients with transvenous pacing leads and transcatheter tricuspid valve-in-valve replacement in congenital heart disease, including Ebstein anomaly.5,8, 9, 10, 11 However, these reports involved either noncongenital anatomies or failed tricuspid bioprostheses rather than native valve replacement. To our knowledge, native valve EVOQUE TTVR in complex ACHD with a transvalvular pacing lead has not previously been described. The combination of distorted right heart geometry from prior surgical reconstruction and lead-related leaflet tethering resulted in significant procedural challenges, including delivery system septal bias. Despite this, successful implantation was achieved with favorable early hemodynamic and clinical outcomes. Conclusions This case highlights the importance of meticulous multimodality imaging, procedural planning, and Heart Team collaboration in extending transcatheter therapies to increasingly complex patients. As TTVR technologies continue to evolve, their application in patients with congenital heart disease—traditionally under-represented in clinical trials—will require careful patient selection and ongoing evaluation of long-term outcomes. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.Take-Home Messages•Transcatheter tricuspid valve replacement can be successfully performed in selected patients with complex congenital heart disease and transvenous pacing leads who are not candidates for surgery or transcatheter edge-to-edge repair.•Meticulous multimodality imaging and Heart Team planning are critical to address anatomical complexity and optimize procedural success. Take-Home Messages •Transcatheter tricuspid valve replacement can be successfully performed in selected patients with complex congenital heart disease and transvenous pacing leads who are not candidates for surgery or transcatheter edge-to-edge repair.•Meticulous multimodality imaging and Heart Team planning are critical to address anatomical complexity and optimize procedural success. •Transcatheter tricuspid valve replacement can be successfully performed in selected patients with complex congenital heart disease and transvenous pacing leads who are not candidates for surgery or transcatheter edge-to-edge repair. Transcatheter tricuspid valve replacement can be successfully performed in selected patients with complex congenital heart disease and transvenous pacing leads who are not candidates for surgery or transcatheter edge-to-edge repair. •Meticulous multimodality imaging and Heart Team planning are critical to address anatomical complexity and optimize procedural success. Meticulous multimodality imaging and Heart Team planning are critical to address anatomical complexity and optimize procedural success.